Posters

On this page, browse and view scientific posters supported by Biogen and presented at key SMA congresses and events

All congresses
MDA
WMS
AAN
AOMC
EAN
Cure SMA
EPNS
SMA Europe
All congresses
All years
2023
2024
2021
2022
All years
All topics
SHINE
Konectom
Realworld data
Genetics
RESPONSE
Other
Natural history
CHERISH
Newborn screening
ENDEAR
NURTURE
ASCEND
All topics
Baseline Plasma pNF-H Chain Level Is Associated With Future Motor Function In Nusinersen-Treated Individuals With Later-onset SMA

Format: PowerPoint
Author: Farrar MA, et al.

Open poster
Impact of Baseline Characteristics and Eligibility Criteria on Outcomes in Children with Presymptomatic Spinal Muscular Atrophy (SMA) in NURTURE

Format: PowerPoint
Author: Crawford TO, et al

Open poster
Longitudinal Changes in Items of the Revised Upper Limb Module in Later-Onset Spinal Muscular Atrophy: Results from CHERISH/SHINE

Format: PowerPoint
Author: Montes J, et al

Open poster
Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with Spinal Muscular Atrophy Treated With Nusinersen After Onasemnogene Abeparvovec

Format: PowerPoint
Author: Brandsema JF, et al

Open poster
Impact of Baseline Characteristics and Eligibility Criteria on Outcomes in Children With Presymptomatic Spinal Muscular Atrophy in NURTURE

Format: Poster
Author: Finkel RS, et al

Open poster
Developing a Digital Physical Exercise Solution for People Living With Neuromuscular Disease: Results From a Co-creation Process

Format: PowerPoint
Author: Montes J, et al

Open poster
Effectiveness of Nusinersen in Individuals With Infantile-onset Spinal Muscular Atrophy: A Systematic Literature Review and Meta-Analysis of Clinical Trials and Real-world Studies

Format: PowerPoint
Author: Paradis AD, et al

Open poster
Characteristics of SHINE Study Participants Who Started Concomitant Risdiplam While on Nusinersen

Format: PowerPoint
Author: Castro D, et al

Open poster
Interim Results From the Ongoing RESPOND Study Evaluating Nusinersen in Children With Spinal Muscular Atrophy Previously Treated With Onasemnogene Abeparvovec

Format: PowerPoint
Author: Proud C, et al

Open poster
Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with SMA Treated With Nusinersen After Onasemnogene Abeparvovec

Format: PDF
Author: Masson R. et al

Open poster
A Global Disease Registry Strategy for Generating Real-world (RW) Evidence in Spinal Muscular Atrophy (SMA): Overview and Recent Progress

Format: PDF
Author: Paradis A. et al

Open poster

Biogen-175727-HK-09/22

Terms of Use Privacy Policy Cookies

The contents and the materials available for download in this website is intended for scientific education to healthcare professionals only, and should not be copied, reproduced or further distributed by recipient.

Last Updated April 2024

ⓒ Biogen 2024